2310047O13Rik Activators are a diverse set of chemical compounds that target various cellular signaling pathways to indirectly enhance the functional activity of2310047O13Rik. These activators initiate a cascade of biochemical events that lead to the heightened activity of 2310047O13Rik within its specific cellular context. For instance, Forskolin, by elevating intracellular cyclic AMP (cAMP), indirectly promotes 2310047O13Rik activity through protein kinase A (PKA) activation, which can phosphorylate proteins within the pathway that 2310047O13Rik is a part of, thereby enhancing its function. Similarly, PMA, as an activator of protein kinase C (PKC), may influence 2310047O13Rik by initiating phosphorylation events downstream that are beneficial to 2310047O13Rik's role. Calcium flux plays a pivotal role as well, with compounds such as Ionomycin and A23187, which serve as ionophores, indirectly augmenting 2310047O13Rik's function by raising intracellular calcium levels and activating calcium-dependent protein kinases that could interact with 2310047O13Rik's pathway. Inhibition of PI3K by compounds like LY294002 and Wortmannin is another avenue through which 2310047O13Rik's activity may be enhanced, as alterations in PI3K/Akt signaling can lead to the activation of alternative pathways that involve 2310047O13Rik.
The modulation of kinase activity is a common theme among 2310047O13Rik activators. U0126 and SB203580, which inhibit MEK and p38 MAPK respectively, shift the signaling equilibrium in a manner that could favor the activation of pathways where 2310047O13Rik operates. The kinase inhibitors Epigallocatechin gallate (EGCG) and Staurosporine may also exert a similar effect by reducing competitive or negative regulation of pathways associated with 2310047O13Rik. The specific inhibition of tyrosine kinases by Genistein can lead to an environment where 2310047O13Rik's pathways are less contested, potentially enhancing its activity. Collectively, these chemicals act on distinctive signaling routes that converge on regulating the activity of 2310047O13Rik, ensuring that its functional capacity within the cell is maximized without directly influencing the expression or direct activation of the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that promotes the phosphorylation of target proteins. Activated PKC may increase the functional activity of 2310047O13Rik through downstream signaling pathways that involve protein phosphorylation. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. The elevated calcium may indirectly enhance 2310047O13Rik activity by activating calcium-dependent protein kinases that interact with 2310047O13Rik's pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can lead to altered downstream signaling. By inhibiting PI3K, LY294002 could indirectly enhance 2310047O13Rik activity by modulating pathways where PI3K suppression results in 2310047O13Rik pathway activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate modulates sphingolipid signaling pathways, which could lead to the enhanced activity of 2310047O13Rik by altering the balance of cellular signaling that converges on the functional pathways of 2310047O13Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore that increases intracellular calcium levels, potentially enhancing 2310047O13Rik activity by activating calcium-dependent signaling pathways that 2310047O13Rik may be part of. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can shift signaling balance to favor pathways that could activate 2310047O13Rik. Enhanced 2310047O13Rik activity could result from the inhibition of p38 MAPK and its downstream effects. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may enhance 2310047O13Rik activity by inhibiting kinases that compete with or negatively regulate pathways involving 2310047O13Rik. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a protein kinase inhibitor that, through its broad-spectrum action, could selectively activate pathways associated with 2310047O13Rik by inhibiting kinases that otherwise suppress 2310047O13Rik's pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that could enhance the activity of 2310047O13Rik by reducing competitive signaling via tyrosine kinase pathways, potentially leading to the activation of related pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that could indirectly enhance the activity of 2310047O13Rik by altering PI3K/Akt signaling, potentially affecting pathways that 2310047O13Rik is involved in. | ||||||